Comment on "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial"

被引:0
|
作者
Ferreira, Daniel
机构
关键词
EARLY DISCHARGE; SEVERITY INDEX;
D O I
10.1016/j.repc.2012.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although practice guidelines recommend outpatient care for selected, haemodynamically stable patients with pulmonary embolism, most treatment is presently inpatient based. We aimed to assess non-inferiority of outpatient care compared with inpatient care. Methods: We undertook an open-label, randomised non-inferiority trial at 19 emergency departments in Switzerland, France, Belgium, and the USA. We randomly assigned patients with acute, symptomatic pulmonary embolism and a low risk of death (pulmonary embolism severity index risk classes I or II) with a computer-generated randomisation sequence (blocks of 2-4) in a 1:1 ratio to initial outpatient (ie, discharged from hospital <= 24 h after randomisation) or inpatient treatment with subcutaneous enoxaparin (>= 5 days) followed by oral anticoagulation (>= 90 days). The primary outcome was symptomatic, recurrent venous thromboembolism within 90 days; safety outcomes included major bleeding within 14 or 90 days and mortality within 90 days. We used a non-inferiority margin of 4% for a difference between inpatient and outpatient groups. We included all enrolled patients in the primary analysis, excluding those lost to follow-up. This trial is registered with ClinicalTrials.gov, number NCT00425542. Findings: Between February, 2007, and June, 2010, we enrolled 344 eligible patients. In the primary analysis, one (0.6%) of 171 outpatients developed recurrent venous thromboembolism within 90 days compared with none of 168 inpatients (95% upper confidence limit [UCL] 2.7%; p = 0.011). Only one (0.6%) patient in each treatment group died within 90 days (95% UCL 2.1%; p = 0.005), and two (1.2%) of 171 outpatients and no inpatients had major bleeding within 14 days (95% UCL 3.6%; p = 0.031). By 90 days, three (1.8%) outpatients but no inpatients had developed major bleeding (95% UCL 4.5%; p = 0.086). Mean length of stay was 0.5 days (SD 1.0) for outpatients and 3.9 days (SD 3.1) for inpatients. Interpretation: In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care.
引用
收藏
页码:263 / 264
页数:2
相关论文
共 50 条
  • [41] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
    Wang, Shu-Lian
    Fang, Hui
    Song, Yong-Wen
    Wang, Wei-Hu
    Hu, Chen
    Liu, Yue-Ping
    Jin, Jing
    Liu, Xin-Fan
    Yu, Zi-Hao
    Ren, Hua
    Li, Ning
    Lu, Ning-Ning
    Tang, Yu
    Tang, Yuan
    Qi, Shu-Nan
    Sun, Guang-Yi
    Peng, Ran
    Li, Shuai
    Chen, Bo
    Yang, Yong
    Li, Ye-Xiong
    LANCET ONCOLOGY, 2019, 20 (03): : 352 - 360
  • [42] Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
    Halton, Jacqueline
    Brandao, Leonardo R.
    Luciani, Matteo
    Bomgaars, Lisa
    Chalmers, Elizabeth
    Mitchell, Lesley G.
    Nurmeev, Ildar
    Sharathkumar, Anjali
    Svirin, Pavel
    Gorbatikov, Kirill
    Tartakovsky, Igor
    Simetzberger, Monika
    Huang, Fenglei
    Sun, Zhichao
    Kreuzer, Jorg
    Gropper, Savion
    Reilly, Paul
    Brueckmann, Martina
    Albisetti, Manuela
    LANCET HAEMATOLOGY, 2021, 8 (01): : E22 - E33
  • [43] Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
    l'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Nurmohamed, Michael T.
    van Vollenhoven, Ronald F.
    Rispens, Theo
    Boers, Maarten
    Wolbink, Gerrit Jan
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 484 - 487
  • [44] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Cochereau, D.
    Lecuru, F.
    ONCOLOGIE, 2015, 17 (11-12) : 595 - 596
  • [45] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Kehoe, Sean
    Hook, Jane
    Nankivell, Matthew
    Jayson, Gordon C.
    Kitchener, Henry
    Lopes, Tito
    Luesley, David
    Perren, Timothy
    Bannoo, Selina
    Mascarenhas, Monica
    Dobbs, Stephen
    Essapen, Sharadah
    Twigg, Jeremy
    Herod, Jonathan
    McCluggage, Glenn
    Parmar, Mahesh
    Swart, Ann-Marie
    LANCET, 2015, 386 (9990): : 249 - 257
  • [46] Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
    Yang, Wenying
    Liu, Jie
    Shan, Zhongyan
    Tian, Haoming
    Zhou, Zhiguang
    Ji, Qiuhe
    Weng, Jianping
    Jia, Weiping
    Lu, Juming
    Liu, Jing
    Xu, Yuan
    Yang, Zhaojun
    Chen, Wei
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (01): : 46 - 55
  • [47] Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial
    Imamura, Hiroshi
    Kurokawa, Yukinori
    Tsujinaka, Toshimasa
    Inoue, Kentaro
    Kimura, Yutaka
    Iijima, Shohei
    Shimokawa, Toshio
    Furukawa, Hiroshi
    LANCET INFECTIOUS DISEASES, 2012, 12 (05): : 381 - 387
  • [48] Cloxacillin versus pristinamycin for superficial pyodermas: A randomized, open-label, non-inferiority study
    Chosidow, O
    Bernard, P
    Berbis, P
    Humbert, P
    Crickx, B
    Jarlier, V
    DERMATOLOGY, 2005, 210 (04) : 370 - 374
  • [49] Telemedical support for prehospital emergency medical service in severe emergencies: an open-label randomised non-inferiority clinical trial
    Ana Kowark
    Marc Felzen
    Sebastian Ziemann
    Stephanie Wied
    Michael Czaplik
    Stefan K. Beckers
    Jörg C. Brokmann
    Ralf-Dieter Hilgers
    Rolf Rossaint
    Critical Care, 27
  • [50] Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial
    Linares-Espinos, Estefania
    Sanchez-Salas, Rafael
    EUROPEAN UROLOGY, 2019, 75 (01) : 199 - 199